| Parent Drug Name | Name of Impurity | Catalogue No. | |
|---|---|---|---|
| Aramchol | Aramchol Glycine Conjugate | VL6800002 | View |
Aramchol Impurities
| Parent Drug Name | Name of Impurity | Catalogue No. | |
|---|---|---|---|
| Aramchol | Aramchol Glycine Conjugate | VL6800002 | View |
[rfq_list]
| Catalogue No. | VL6800002 |
| CAS No. | N/A |
| Molecular Formula | C46H82N2O6 |
| Molecular Weight | 759.15 g/mol |
| Parent drug | Aramchol |
| IUPAC Name | 2-((R)-4-((3S, 5S, 7R, 8R, 9S, 10S, 12S, 13R, 14S, 17R)-7, 12-dihydroxy-3-icosanamido-10, 13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)acetic acid |
| Synonyms | N/A |
| References | Sumida, Yoshio, and Masashi Yoneda. “Current and Future Pharmacological Therapies for NAFLD/NASH.” Journal of Gastroenterology, vol. 53, no. 3, Dec. 2017, pp. 362–76, https://doi.org/10.1007/s00535-017-1415-1. |
| Status | In-stock |
| ListName | Aramchol Glycine Conjugate |
| Exclusively Supplied by Veeprho | Exclusively Supplied by Veeprho |
"*" indicates required fields
